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deterioration to death in less than 3 months. However, with 
obvious radiological evidence of both intrapulmonary and 
pleural disease, it was important to avoid the pitfall of 
ascribing his respiratory symptoms to these, and failing to 
consider endobronchial disease. Stridor in this context 
should always prompt a search for a lesion in the main 
airway, as the advent of newer endobronchial therapies, 
such as stenting, brachytherapy or laser (6), may allow 
useful symptom palliation. 
Some reports suggest better outcomes in patients 
treated for endobronchial metastases. The report of three 
patients with endobronchial metastases from sarcoma 
showed a moderate survival, with one patient dying 
5 months after the discovery of endobronchial metas- 
tases and the other two still being alive 11 and 14 months 
after this finding. The present case is in stark contrast to 
this. The poorer outcome in this case reflects not only 
the extensive nature of this patient’s extrabronchial 
disease, but also that he had previously failed to 
respond markedly to aggressive chemotherapy and 
radiotherapy. 
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Introduction 
Non-small cell lung cancer (NSCLC) is a common cause of 
death world-wide and is less responsive to chemotherapy 
than small cell lung cancer. Dermatomyositis is a rare 
condition in Chinese and is classically associated with 
underlying malignancy, although this association has been 
recently doubted by some authors (1,2). Association of 
dermatomyositis with lung cancer is less doubtful, although 
a causal relationship has not been firmly established (3). 
Whilst it is known that cancer-associated dermatomyositis 
is often more refractory to standard treatment such as the 
administration of systemic corticosteroids, little is known of 
the response of NSCLC-associated dermatomyositis to 
chemotherapy directed at the underlying lung cancer. The 
present case report describes a case of a 5%year old man 
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who presented with dermatomyositis and was found to 
have extensive metastatic NSCLC. Both the NSCLC and 
dermatomyositis responded well to a combination of 
mitomycin-C (M), ifosphamide (I) and cis-platinum (P). 
Case History 
A 5%year old ex-smoker presented with a 2-month history 
of an erythematous and pruritic rash affecting his face 
and limbs which was resistant to topical steroid therapy 
(Plate 1). Deterioration and ulceration of the skin was 
accompanied by development of progressively disabling 
symmetrical limb girdle weakness (including inability to 
stand from sitting position and flex the neck), swallowing 
difficulty and weight loss, although there were no respirat- 
ory symptoms. Physical examination revealed an erythema- 
tous rash affecting the described areas, symmetrical limb 
girdle weakness (415) and nasal regurgitation, but there was 
no other abnormalities. 
A chest X-ray showed a right hilar shadow which 
was revealed on thoracic computerized tomography (CT) 
(Plate 2) to be a 3 cm irregular mass situated anterior to the 
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PLATE 1. Photograph of the patient showing thickened 
and erythematous skin before the commencement of 
chemotherapy. 
right main bronchus. There was also ipsilateral mediastinal 
and contralateral hilar lymphadenopathy, and a pleural 
effusion. Fibre-optic bronchoscopy detected a tumour 
obstructing the right middle lobe bronchus, but biopsy was 
non-diagnostic. Thoracoscopic biopsy of mediastinal 
lymph nodes revealed NSCLC. Bone scan, other screening 
tests including liver function tests, and abdominal CT 
showed no other metastases. The tumour was therefore 
staged as III-b (T3 N3 MO). 
An electromyographic study (of the deltoid and biceps) 
revealed myopathic changes, but the creatinine kinase level 
was 190 MU/l (normal 66-268 MU/l) even before chemo- 
therapy. Muscle biopsy showed foci of mild interstitial 
lymphocytic infiltration with associated fibrosis, and skin 
biopsy showed epidermal thinning and dermal peri-vascular 
and peri-adnexal chronic inflammatory infiltration. Other 
investigations including routine biochemistry screen, auto- 
antibodies and plasma complement levels were normal. The 
patient, therefore, fulfilled the diagnostic criteria (4,5) for 
dermatomyositis which had no identifiable aetiology other 
than NSCLC. 
The patient subsequently underwent palliative radio- 
therapy to the right lung and mediastinum (30 Gy in 10 
fractions) to prevent lobar collapse. Two months following 
PLATE 2. Thoracic computerized tomograph of the 
patient (pre-chemotherapy) showing a mass lesion at the 
right hilum anterior to the right main bronchus and 
mediastinal lymphadenopathy. 
,that, he received a course of chemotherapy (four cycles each 
separated by 2 weeks) which was a combination of 
mitomycin-C (8 mg rn-’ for 1 day at first and third cycles), 
ifosphamide (1250 mg for 2 days of each cycle) and cis- 
platinum (60 mg m ~ 2 for 1 day of each cycle). Seven days 
after the first cycle of MIP, the patient suddenly noted 
complete return of his limb girdle power and ceased having 
nasal regurgitation. After the second MIP cycle, he 
reported further resolution of his rash which was not 
detectable after the third cycle. Thoracic CT performed 4 
months after completion of MIP therapy and other screen- 
ing tests revealed stable disease (defined as a lack of 
progression of tumour size and extent, and no further 
metastases). Mild generalized thickening of the skin was 
noted 8 months after the initiation of MIP, which pro- 
gressed very slowly and was accompanied by CT evidence 
of enlargement of mediastinal, and appearance of axillary 
lymph notes. At the time of writing, 25 months after 
the initiation of MIP therapy, the patient had remained 
otherwise well and been free of respiratory symptoms. 
Discussion 
Despite classical description, there is still controversy on 
whether or not there is a casual relationship between 
dermatomyositis and underlying cancer (1,2). As the muscle 
and skin histological features in dermatomyositis are in- 
distinguishable, irrespective of the underlying aetiology (3), 
dermatomyositis may, therefore, be a homogenous disease 
which only occurs coincidentally with malignancy. Lung 
cancer can present in a variety of para-neoplastic neuro- 
muscular syndromes including muscle atrophy, necrobiotic 
myopathy and Lambert-Eaton syndrome (3). Dermato- 
myositis is a rare disease in Chinese (6) and is usually 
associated with nasopharyngeal carcinoma (6). Little is 
known of the response of dermatomyositis to anti-cancer 
chemotherapy, nor has there been a definitive casual 
relationship between lung cancer and dermatomyositis. 
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Patients with lung cancer usually have little chance of 
curative treatment and have a poor prognosis. Most lung 
cancers are of the NSCLC type, and a small but significant 
proportion of these patients may benefit from cis-platinum- 
based poly-chemotherapy in terms of survival and symptom 
palliation (7). A combination of mitomycin-C, ifosphamide 
and cis-platinum has been shown to give a response rate in 
28-39% of NSCLC patients (8,9). By using a similar regime 
described in this case report, a response rate of 53% has 
been observed in Hong Kong (10). The patient described in 
this case report has demonstrated stable NSCLC with 
excellent palliation from MIP chemotherapy. 
Dermatomyositis associated with malignancy is often 
refractory to standard treatment such as systemic cortic- 
osteroids. It has been shown that some of these resistant 
cases may be more responsive to u-globulin, azathioprine, 
chlorambucil, methotrexate, cyclosporine and cyclo- 
phosphamide (11). The response of dermatomyositis to 
the constituents of the MIP regime has not been reported 
previously although these cytotoxic drugs might have also 
exerted some immunomodulating effects. The similarity 
between cyclophosphamide and ifosphamide might also 
explain the efficacy of the MIP regime on the dermato- 
myositis, although altogether only eight doses of ifos- 
phamide had been given. Alternatively, the regression of 
the dermatomyositis might have been the result of pallia- 
tive radiotherapy. The improvement of dermatomyositis 
had been sustained until CT evidence of disease progres- 
sion, aqd it is, therefore, highly probable that the 
improvement of dermatomyositis was due to the control 
of the underlying NSCLC by’ the chemotherapy regime. 
This constitutes good circumstantial evidence for a casual 
association between NSCLC and dermatomyositis. The 
authors’ experience on this case suggests that intensive 
chemotherapy for underlying lung cancer may offer excel- 
lent palliation for dermatomyositis associated with lung 
cancers. 
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Lung abscess with squamous epithelial lining 
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Introduction Case Report 
A case of an epithelialized lung abscess in a patient with 
non-Hodgkin’s lymphoma and chronic chest infection is 
In April 1993, a 52-year-old man was admitted with fever. 
reyiorted. The patient expectorated pulmonary abscess 
The patient was known from many previous admissions 
meinbranes lined with squamous epithelium and a para- 
with non-Hodgkin’s lymphoma which had developed into 
keya‘totic plug during thoracocentesis. 
paraproteinaemia and hyperviscosity syndrome treated 
with plasmapheresis, prednisolone and cyclophosphamide. 
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In 1991, the patient had presented with fever. An air-fluid 
interface was apparent in one and later in two cavities in the 
right lung on the chest radiographs. He was treated un- 
successfully with antibiotics. Repeated thoracocentesis and 
bronchoscopic drainage both failed to accomplish a cure. 
